145 related articles for article (PubMed ID: 11528242)
1. Effect of weekly or successive iron supplementation on erythropoietin doses in patients receiving hemodialysis.
Kato A; Hamada M; Suzuki T; Maruyama T; Maruyama Y; Hishida A
Nephron; 2001 Sep; 89(1):110-2. PubMed ID: 11528242
[TBL] [Abstract][Full Text] [Related]
2. [Iron replacement in hemodialysis patients with a normal serum ferritin level].
Riedel MK; Morgenstern T
Dtsch Med Wochenschr; 2004 Sep; 129(36):1849-53. PubMed ID: 15368155
[TBL] [Abstract][Full Text] [Related]
3. Anemia and carnitine supplementation in hemodialyzed patients.
Kletzmayr J; Mayer G; Legenstein E; Heinz-Peer G; Leitha T; Hörl WH; Kovarik J
Kidney Int Suppl; 1999 Mar; 69():S93-106. PubMed ID: 10084293
[TBL] [Abstract][Full Text] [Related]
4. Intravenous ascorbic acid in hemodialysis patients with functional iron deficiency: a clinical trial.
Giancaspro V; Nuzziello M; Pallotta G; Sacchetti A; Petrarulo F
J Nephrol; 2000; 13(6):444-9. PubMed ID: 11132761
[TBL] [Abstract][Full Text] [Related]
5. Targeting higher ferritin concentrations with intravenous iron dextran lowers erythropoietin requirement in hemodialysis patients.
DeVita MV; Frumkin D; Mittal S; Kamran A; Fishbane S; Michelis MF
Clin Nephrol; 2003 Nov; 60(5):335-40. PubMed ID: 14640239
[TBL] [Abstract][Full Text] [Related]
6. Mathematical approach for estimating iron needs in hemodialysis patients on erythropoietin therapy.
Tarng DC; Huang TP; Chen TW
Am J Nephrol; 1997; 17(2):158-64. PubMed ID: 9096447
[TBL] [Abstract][Full Text] [Related]
7. The evaluation of postdialysis L-carnitine administration and its effect on weekly requiring doses of rHuEPO in hemodialysis patients.
Kadiroglu AK; Yilmaz ME; Sit D; Kara IH; Isikoglu B
Ren Fail; 2005; 27(4):367-72. PubMed ID: 16060121
[TBL] [Abstract][Full Text] [Related]
8. Association between transferrin receptor-ferritin index and conventional measures of iron responsiveness in hemodialysis patients.
Chen YC; Hung SC; Tarng DC
Am J Kidney Dis; 2006 Jun; 47(6):1036-44. PubMed ID: 16731299
[TBL] [Abstract][Full Text] [Related]
9. Orally administrated Juzen-taiho-to/TJ-48 ameliorates erythropoietin (rHuEPO)-resistant anemia in patients on hemodialysis.
Nakamoto H; Mimura T; Honda N
Hemodial Int; 2008 Oct; 12 Suppl 2():S9-S14. PubMed ID: 18837771
[TBL] [Abstract][Full Text] [Related]
10. Importance of iron supply for erythropoietin therapy.
Sunder-Plassmann G; Hörl WH
Nephrol Dial Transplant; 1995 Nov; 10(11):2070-6. PubMed ID: 8643170
[TBL] [Abstract][Full Text] [Related]
11. Erythropoietin therapy in pre-dialysis patients with chronic renal failure: lack of need for parenteral iron.
Trivedi HS; Brooks BJ
Am J Nephrol; 2003; 23(2):78-85. PubMed ID: 12481145
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of a low-dose intravenous iron sucrose regimen in peritoneal dialysis patients.
Dittrich E; Schillinger M; Sunder-Plassmann G; Hörl WH; Vychytil A
Perit Dial Int; 2002; 22(1):60-6. PubMed ID: 11929146
[TBL] [Abstract][Full Text] [Related]
13. Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients.
Vanrenterghem Y; Bárány P; Mann JF; Kerr PG; Wilson J; Baker NF; Gray SJ;
Kidney Int; 2002 Dec; 62(6):2167-75. PubMed ID: 12427142
[TBL] [Abstract][Full Text] [Related]
14. Comparative response to single or divided doses of parenteral iron for functional iron deficiency in hemodialysis patients receiving erythropoietin (EPO).
Saltissi D; Sauvage D; Westhuyzen J
Clin Nephrol; 1998 Jan; 49(1):45-8. PubMed ID: 9491286
[TBL] [Abstract][Full Text] [Related]
15. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
[TBL] [Abstract][Full Text] [Related]
16. Dialysate iron therapy: infusion of soluble ferric pyrophosphate via the dialysate during hemodialysis.
Gupta A; Amin NB; Besarab A; Vogel SE; Divine GW; Yee J; Anandan JV
Kidney Int; 1999 May; 55(5):1891-8. PubMed ID: 10231452
[TBL] [Abstract][Full Text] [Related]
17. Protocolized anemia management with erythropoietin in hemodialysis patients: a randomized controlled trial.
Brimble KS; Rabbat CG; McKenna P; Lambert K; Carlisle EJ
J Am Soc Nephrol; 2003 Oct; 14(10):2654-61. PubMed ID: 14514745
[TBL] [Abstract][Full Text] [Related]
18. Reduction in erythropoietin doses by the use of chronic intravenous iron supplementation in iron-replete hemodialysis patients.
Chang CH; Chang CC; Chiang SS
Clin Nephrol; 2002 Feb; 57(2):136-41. PubMed ID: 11863124
[TBL] [Abstract][Full Text] [Related]
19. Sodium ferric gluconate complex therapy in anemic children on hemodialysis.
Warady BA; Zobrist RH; Wu J; Finan E;
Pediatr Nephrol; 2005 Sep; 20(9):1320-7. PubMed ID: 15971073
[TBL] [Abstract][Full Text] [Related]
20. Economic appraisal of maintenance parenteral iron administration in treatment of anaemia in chronic haemodialysis patients.
Sepandj F; Jindal K; West M; Hirsch D
Nephrol Dial Transplant; 1996 Feb; 11(2):319-22. PubMed ID: 8671786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
